Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations
File(s)CMI_1654_edit_report.pdf (163.74 KB) mmc1.pdf (278.96 KB)
Accepted version
Supporting information
Author(s)
Lochen, A
Anderson, RM
Type
Journal Article
Abstract
Background
Of over 90 serotypes of Streptococcus pneumoniae, only seven were included in the first pneumococcal conjugate vaccine (PCV). While PCV reduced the disease incidence, in part because of a herd immunity effect, a replacement effect was observed whereby disease was increasingly caused by serotypes not included in the vaccine. Dynamic transmission models can account for these effects to describe post-vaccination scenarios, whereas economic evaluations can enable decision-makers to compare vaccines of increasing valency for implementation.
Aim
The aim of this review was to examine epidemiological and economic models and their assumptions for their potential contributions to future research and immunisation policy.
Sources
Pubmed, Scopus, Ovid, ISI Web of Knowledge, Centre of Reviews and Dissemination (CRD) databases were searched.
Content
Twenty-three dynamic transmission models and 21 economic models were retrieved and reviewed. Published models employed various templates, revealing several key uncertainties regarding the biology and epidemiology of pneumococcal infection. While models suggested that PCVs will reduce the burden of disease, the extent to which they are predicted to do so depended on various assumptions regarding features of pneumococcal infection and epidemiology that governed PCV cost-effectiveness as well. Such features include the duration of protection and competitive interactions between serotypes, which are unclear at present, but which directly relate to herd immunity and serotype replacement.
Implications
Economic evaluations are not typically based on transmission dynamic models and hence omit indirect herd immunity effects. The two tools could be used in conjunction to inform decision-makers on vaccine implementation, but so far there have been few attempts to build economic evaluations on transmission dynamic models, and none in this field. Future directions for research could include studies to evaluate key parameters for the models involving herd immunity, serotype competition and the natural history of infection.
Of over 90 serotypes of Streptococcus pneumoniae, only seven were included in the first pneumococcal conjugate vaccine (PCV). While PCV reduced the disease incidence, in part because of a herd immunity effect, a replacement effect was observed whereby disease was increasingly caused by serotypes not included in the vaccine. Dynamic transmission models can account for these effects to describe post-vaccination scenarios, whereas economic evaluations can enable decision-makers to compare vaccines of increasing valency for implementation.
Aim
The aim of this review was to examine epidemiological and economic models and their assumptions for their potential contributions to future research and immunisation policy.
Sources
Pubmed, Scopus, Ovid, ISI Web of Knowledge, Centre of Reviews and Dissemination (CRD) databases were searched.
Content
Twenty-three dynamic transmission models and 21 economic models were retrieved and reviewed. Published models employed various templates, revealing several key uncertainties regarding the biology and epidemiology of pneumococcal infection. While models suggested that PCVs will reduce the burden of disease, the extent to which they are predicted to do so depended on various assumptions regarding features of pneumococcal infection and epidemiology that governed PCV cost-effectiveness as well. Such features include the duration of protection and competitive interactions between serotypes, which are unclear at present, but which directly relate to herd immunity and serotype replacement.
Implications
Economic evaluations are not typically based on transmission dynamic models and hence omit indirect herd immunity effects. The two tools could be used in conjunction to inform decision-makers on vaccine implementation, but so far there have been few attempts to build economic evaluations on transmission dynamic models, and none in this field. Future directions for research could include studies to evaluate key parameters for the models involving herd immunity, serotype competition and the natural history of infection.
Date Issued
2020-01-01
Date Acceptance
2019-04-22
Citation
Clinical Microbiology and Infection, 2020, 26 (1), pp.60-70
ISSN
1198-743X
Publisher
Elsevier
Start Page
60
End Page
70
Journal / Book Title
Clinical Microbiology and Infection
Volume
26
Issue
1
Copyright Statement
© 2019 Elsevier Ltd. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence http://creativecommons.org/licenses/by-nc-nd/4.0/
Sponsor
GlaxoSmithKline Services Unlimited
Medical Research Council (MRC)
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000505052600010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Grant Number
N/A
MR/R015600/1
Subjects
Science & Technology
Life Sciences & Biomedicine
Infectious Diseases
Microbiology
Economic evaluation
Health economics
Infectious disease epidemiology
Infectious disease modelling
Invasive pneumococcal disease
Pneumococcal conjugate vaccine
Pneumococcus
Streptococcus pneumoniae
Vaccines
NONTYPABLE HAEMOPHILUS-INFLUENZAE
ACUTE OTITIS-MEDIA
COST-EFFECTIVENESS
STREPTOCOCCUS-PNEUMONIAE
PROTEIN-D
SEROTYPE REPLACEMENT
PHID-CV
EPIDEMIOLOGIC EVIDENCE
INFANT VACCINATION
ACQUIRED-IMMUNITY
Publication Status
Published
Date Publish Online
2019-05-02